Date:	9/29/2023
Your Name:	Kaj Blennow
Manuscript Title:	Plasma biomarkers of Alzheimer's disease and related dementias in American Indians: the Strong Heart Study
Manuscript Number (if known):	ADJ-D-23-00799

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	
		Time frame: past 36 months	3
2	Grants or contracts from any entity (if not	None Swedish Research Council (#2017-00915 and #2022-0	00732) To the Institute
	indicated in item #1 above).	the Swedish state under the agreement between the government and the County Councils, the ALF-agree (#ALFGBG-715986 and #ALFGBG-965240)	Swedish To the Institute
		the Swedish Alzheimer Foundation (#AF-930351, #AF #AF-968270)	F-939721 and To the Institute
		Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022	·
		the Alzheimer's Association 2021 Zenith Award (ZEN-	,
		the Alzheimer's Association 2022-2025 Grant (SG-23-	-1038904 QC) To the Institute

		Name all entities with whom you have thi relationship or indicate none (add rows as		Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None     Non		
4	Consulting fees	Acumen ALZpath BioArctic Biogen Eisai Lilly Ono Pharma Roche Diagnostics Siemens Healthineers Biogen	Consulta Consulta Consulta Consulta Consulta Consulta Consulta Consulta Produce payment	
		Eisai  Roche Diagnostics	payment	d/participated in educational programs with
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None □		
6	Payment for expert testimony	None		
7	Support for attending meetings and/or travel	None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Julius Clinical Novartis	To me To me
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
r 1	Please place an "X" next to the following statement to indicate your agreement:		
	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

3 12/13/2021 ICMJE Disclosure Form

Date:	10/31/2023
Your Name:	Dedra Buchwald
Manuscript Title:	Plasma biomarkers of Alzheimer's disease and related dementias in American Indians: the Strong Heart Study
Manuscript Number (if known):	ADJ-D-23-00799

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 mont	ns
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	No COIs pertinent to ADRD or this study.	
Plea 🖂	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	10/31/2023
Your Name:	Thomas Grabowski
Manuscript Title:	Plasma biomarkers of Alzheimer's disease and related dementias in American Indians: the Strong Heart Study
Manuscript Number (if known):	ADJ-D-23-00799

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	NIA P30 AG066509 NIA P50 AG005136	Click the tab key to add additional rows.
		Time frame: past 36 months	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	10/31/2023
Your Name:	WT Longstreth
Manuscript Title:	Plasma biomarkers of Alzheimer's disease and related dementias in American Indians: the Strong Heart Study
Manuscript Number (if known):	ADJ-D-23-00799

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.		Dr. Longstreth receives support from NIH on several projects, including this one.  Click the tab key to add additional rows.
		Time frame: past 36 months	5
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., made to you or to your institution)	
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	[⊠] None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	10/31/2023
Your Name:	Eric Reiman
Manuscript Title:	Plasma biomarkers of Alzheimer's disease and related dementias in American Indians: the Strong Heart Study
Manuscript Number (if known):	ADJ-D-23-00799

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	ADRC Grant Arizona Alzheimer's Consortium	Click the tab key to add additional rows.
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	Co-founder and Advisor, ALZPath	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	10/31/2023
Your Name:	Kristoffer Rhoads
Manuscript Title:	Plasma biomarkers of Alzheimer's disease and related dementias in American Indians: the Strong Heart Study
Manuscript Number (if known):	ADJ-D-23-00799

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Grabowski)  National Institute on Aging K01AG057821 (PI Suchy-Dicey)	funding for Visit 2  Funding for data management, analysis, consensus adjudication  Click the tab key to add additional rows.
		Time frame: past 36 months	5
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None None □	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	2-3 expert witness consultations per year	Payment made to me
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	10/31/2023
Your Name:	Astrid Suchy-Dicey
Manuscript Title:	Plasma biomarkers of Alzheimer's disease and related dementias in American Indians: the Strong Heart Study
Manuscript Number (if known):	ADJ-D-23-00799
In the interest of transparency, we	e ask you to disclose all relationships/activities/interests listed below that are related to the

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Heart Lung and Blood Institute R01HL093086 (PI Buchwald)  National Institute on Aging P50AG005136 (PI Grabowski)  National Institute on Aging K01AG057821 (PI Suchy-Dicey)	University of Washington Alzheimer's Disease Research Center Development Award 2021-2022 (PI Suchy-Dicey)  Click the tab key to add additional rows.
		Time frame: past 36 months	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	As above	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
11	Stock or stock options	None			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None			
13	Other financial or non-financial interests	None			
Plea	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.				

Date:	10/31/2023
Your Name:	Jason G Umans
Manuscript Title:	Plasma Biomarkers of Alzheimer's disease and related dementias in American Indians: The Strong Heart Study
Manuscript Number (if known):	ADJ-D-23-00799

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial planning of the work			
2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item	Infrastructure and study population provided by the Strong Heart Study, NHLBI contracts 75N92019D00027, 75N92019D00028, 75N92019D00029, & 75N92019D00030  Time frame: past 36 months  None	Click the tab key to add additional rows.		
3	#1 above).  Royalties or	None			
	licenses				

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
11	Stock or stock options	None			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None			
13	Other financial or non-financial interests	None			
Plea	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.				

Date:	2023-10-31				
Your Name	: Henrik Zetterberg				
Manuscript	title: Plasma biomarkers	of Alzheimer's disease	and related dementias in	American Indians:	the Strong
Heart Study	1				
Manuscript	number (if known): ADJ-	D-23-00799			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	(e.g., if	cations/Comments payments were made or to your institution)
		Time frame: Since the initial plant	ning of tl	ne work
1	All support for the present manuscript (e.g., funding, provision	HZ is a Wallenberg Scholar supported by from the Swedish Research Council (#202 and #2019-02397), the European Union's Europe research and innovation program under grant agreement No 101053962, State Support for Clinical Research (#ALFG	22-01018 Horizon me wedish GBG-	Payments made to Institution.
	of study materials, medical writing, article processing charges, etc.)	71320), the Alzheimer Drug Discovery For (ADDF), USA (#201809-2016862), the AD Fund and the Alzheimer's Association (#A 831376-C, #ADSF-21-831381-C, and #ADS 831377-C), the Bluefield Project, the Olav Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarin Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research innovation programme under the Marie	Strategic DSF-21- F-21- Thon nor,	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	(e.g., if	ications/Comments f payments were made or to your institution)
	No time limit for this item.	Skłodowska-Curie grant agreement No 86 (MIRIADE), the European Union Joint Pro – Neurodegenerative Disease Research (JPND2021-00694), the National Institute Health and Care Research University Coll London Hospitals Biomedical Research Cand the UK Dementia Research Institute (UKDRI-1003).	gramme for ege entre,	Click the tab key to add additional rows
		Time frame: past 36 m	onths	
2	Grants or contracts	□ None		
	from any entity (if not indicated in item #1 above).	HZ is a Wallenberg Scholar supply by grants from the Swedish Reserved Council (#2022-01018 and #20102397), the European Union's He Europe research and innovation programme under grant agreem 101053962, Swedish State Supply Clinical Research (#ALFGBG-713) the Alzheimer Drug Discovery Foundation (ADDF), USA (#20182016862), the AD Strategic Fundation (#ADSF-21-831376-C, #ADSF-21-831381 and #ADSF-21-831377-C), the Beauty Project, the Olav Thon Foundation Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#F02022) the European Union's Horizon 20 research and innovation program under the Marie Skłodowska-Cungrant agreement No 860197 (MIRIADE), the European Union Programme – Neurodegenerative Disease Research (JPND2021-00) the National Institute for Health Care Research University College	arch 9- orizon ent No ort for (20), (09- and OSF- 1-C, luefield on, the on, (20) onme rie Joint e 694), and	Payments made to Institu

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Specifications/Comments (e.g., if payments were made to you or to your institution)			
		London Hospitals Biomedical Res Centre, and the UK Dementia Res Institute at UCL (UKDRI-1003).			
3	Royalties or licenses	None     ■			
4	Consulting fees	HZ has served at scientific advisor boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinov ALZPath, Annexon, Apellis, Arter Therapeutics, AZTherapies, Cogn Therapeutics, CogRx, Denali, Eisa Nervgen, Novo Nordisk, Optoceu Passage Bio, Pinteon Therapeutic Prothena, Red Abbey Labs, reMY Roche, Samumed, Siemens Healthineers, Triplet Therapeutic Wave.	ras served at scientific advisory rds and/or as a consultant for vie, Acumen, Alector, Alzinova, Path, Annexon, Apellis, Artery rapeutics, AZTherapies, Cognito rapeutics, CogRx, Denali, Eisai, vgen, Novo Nordisk, Optoceutics, age Bio, Pinteon Therapeutics, hena, Red Abbey Labs, reMYND, ne, Samumed, Siemens thineers, Triplet Therapeutics, and		
5	Payment or honoraria for lectures, presentati ons, speakers bureaus, manuscrip	HZ has given lectures in symposi sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and		Payments made to HZ.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	t writing or education al events		
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	None     ■	
8	Patents planned, issued or pending	None     ■	
9	Participati on on a Data Safety Monitorin g Board or Advisory Board	HZ has served at scientific adviso boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinov ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cogn Therapeutics, CogRx, Denali, Eisa Nervgen, Novo Nordisk, Optoceut Passage Bio, Pinteon Therapeutic Prothena, Red Abbey Labs, reMYI Roche, Samumed, Siemens Healthineers, Triplet Therapeutic Wave	a,  ito i, cics, s, ND,

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	(e.g., if	cations/Comments payments were made or to your institution)	
1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	HZ is chair of the Alzheimer's Association Global Biomarker Standardization Consortium.		No payments made.	
1 1	Stock or stock options	□ None  HZ is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program.		Payments made to HZ.	
1 2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None			
1 3	Other financial or non-financial interests	None			

# Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording  $\boxtimes$  of any of the questions on this form.